Author:
Pérez-González Alexandre,Araújo-Ameijeiras Alejandro,Fernández-Villar Alberto,Crespo Manuel,Poveda Eva,Cabrera Jorge Julio,del Campo Víctor,de Araujo Beatriz Gil,Gómez Carlos,Leiro Virginia,Longueira María Rebeca,López-Domínguez Ana,Ramón Lorenzo José,Marcos María,Teresa Pérez María,Patiño Lucia,Pérez Sonia,Pérez-Fernández Silvia,Ramos Cristina,Regueiro Benito,Retresas Cristina,Rivera Tania,Souto Olga,Taboada Isabel,Teijeira Susana,Torres María,Val Vanesa,Viéitez Irene,
Abstract
AbstractSurvivors to COVID-19 have described long-term symptoms after acute disease. These signs constitute a heterogeneous group named long COVID or persistent COVID. The aim of this study is to describe persisting symptoms 6 months after COVID-19 diagnosis in a prospective cohort in the Northwest Spain. This is a prospective cohort study performed in the COHVID-GS. This cohort includes patients in clinical follow-up in a health area of 569,534 inhabitants after SARS-CoV-2/COVID-19 diagnosis. Clinical and epidemiological characteristics were collected during the follow up. A total of 248 patients completed 6 months follow-up, 176 (69.4%) required hospitalization and 29 (10.2%) of them needed critical care. At 6 months, 119 (48.0%) patients described one or more persisting symptoms. The most prevalent were: extra-thoracic symptoms (39.1%), chest symptoms (27%), dyspnoea (20.6%), and fatigue (16.1%). These symptoms were more common in hospitalized patients (52.3% vs. 38.2%) and in women (59.0% vs. 40.5%). The multivariate analysis identified COPD, women gender and tobacco consumption as risk factors for long COVID. Persisting symptoms are common after COVID-19 especially in hospitalized patients compared to outpatients (52.3% vs. 38.2%). Based on these findings, special attention and clinical follow-up after acute SARS-CoV-2 infection should be provided for hospitalized patients with previous lung diseases, tobacco consumption, and women.
Funder
Instituto de Salud Carlos III
Publisher
Springer Science and Business Media LLC